Last reviewed · How we verify
CAR-T-19 cell injection
CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies.
CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies. Used for B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia (B-ALL).
At a glance
| Generic name | CAR-T-19 cell injection |
|---|---|
| Sponsor | Beijing Yongtai Ruike Biotechnology Company Ltd |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets CD19 antigen present on B-cell lymphomas and leukemias, and then reinfusing the engineered cells to attack and eliminate malignant B cells. This approach harnesses the patient's own immune system to provide durable anti-tumor activity.
Approved indications
- B-cell non-Hodgkin lymphoma
- B-cell acute lymphoblastic leukemia (B-ALL)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR-T-19 cell injection CI brief — competitive landscape report
- CAR-T-19 cell injection updates RSS · CI watch RSS
- Beijing Yongtai Ruike Biotechnology Company Ltd portfolio CI